Literature DB >> 32503798

Proof-of-Concept with PROTACs in Prostate Cancer.

.   

Abstract

Preliminary clinical data for ARV-110, a proteolysis-targeting chimera that flags the androgen receptor for degradation, indicate that the drug is safe and shows some efficacy in men with metastatic castration-resistant prostate cancer. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID： 32503798     DOI： 10.1158/2159-8290.CD-NB2020-054

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  16 in total

Review 1.  Clinical and Biological Features of Neuroendocrine Prostate Cancer.

Authors:  Yasutaka Yamada; Himisha Beltran
Journal:  Curr Oncol Rep       Date:  2021-01-12       Impact factor: 5.075

2.  Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.

Authors:  Ga-Yeong Kim; Chae Won Song; Yo-Sep Yang; Na-Rae Lee; Hyung-Seok Yoo; Seung Hwan Son; Soo Jin Lee; Jong Seon Park; Jong Kil Lee; Kyung-Soo Inn; Nam-Jung Kim
Journal:  Molecules       Date:  2021-04-26       Impact factor: 4.411

Review 3.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

4.  Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.

Authors:  Hanna Tukachinsky; Russell W Madison; Jon H Chung; Ole V Gjoerup; Eric A Severson; Lucas Dennis; Bernard J Fendler; Samantha Morley; Lei Zhong; Ryon P Graf; Jeffrey S Ross; Brian M Alexander; Wassim Abida; Simon Chowdhury; Charles J Ryan; Karim Fizazi; Tony Golsorkhi; Simon P Watkins; Andrew Simmons; Andrea Loehr; Jeffrey M Venstrom; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2021-02-08       Impact factor: 13.801

5.  An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA.

Authors:  Jianyuan Zhao; Jing Wang; Xu Pang; Zhenlong Liu; Quanjie Li; Dongrong Yi; Yongxin Zhang; Xiaomei Fang; Tao Zhang; Rui Zhou; Tao Zhang; Zhe Guo; Wancang Liu; Xiaoyu Li; Chen Liang; Tao Deng; Fei Guo; Liyan Yu; Shan Cen
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

Review 6.  E3 ubiquitin ligases: styles, structures and functions.

Authors:  Quan Yang; Jinyao Zhao; Dan Chen; Yang Wang
Journal:  Mol Biomed       Date:  2021-07-30

Review 7.  Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.

Authors:  Yuan Wang; Jing He; Manyu Xu; Qingfeng Xue; Cindy Zhu; Juan Liu; Yaping Zhang; Wenyu Shi
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

Review 8.  The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.

Authors:  Jinmei Jin; Ye Wu; Jinjiao Chen; Yiwen Shen; Lijun Zhang; Hong Zhang; Lili Chen; Hebao Yuan; Hongzhuan Chen; Weidong Zhang; Xin Luan
Journal:  Theranostics       Date:  2020-08-08       Impact factor: 11.556

Review 9.  E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.

Authors:  Tasuku Ishida; Alessio Ciulli
Journal:  SLAS Discov       Date:  2020-11-03       Impact factor: 3.341

Review 10.  Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.

Authors:  Jiayi Lin; Jinmei Jin; Yiwen Shen; Lijun Zhang; Gang Gong; Huiting Bian; Hongzhuan Chen; Dale G Nagle; Ye Wu; Weidong Zhang; Xin Luan
Journal:  Theranostics       Date:  2021-07-13       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.